SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
EntreMed (ENMD)
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
2135 59 0 ENMD
Emcee:  Mark Wise Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2085 <<Sugen is still too expensive.>> Sugen doesn't exist any moretommysdad-5/15/2000
2084 Did this patient (or others) get (enough) Endostatin? If those who were put offStockDoc-5/15/2000
2083 In 1st trials, cancer drug Endostatin disappoints No shrinkage seen in many tumJack Hartmann-5/14/2000
2082 No data (dose response calculated for body weight and tumor mass) are out yet. StockDoc-5/12/2000
2081 Stockdoc you stated when hyping this stock>>>>>>>>>&Bluegreen-5/11/2000
2080 Off topic but worth a read: CELSION CORP> CELN Spencer J. Volk, President Tech Master-5/11/2000
2079 Worth a look people... Celsion Corporation CELN: Celsion is a biomedical reseTech Master-5/11/2000
2078 If I had a chance to work on endostatin (I tried), I would have designed the trStockDoc-5/11/2000
2077 <b>No triumphs seen yet in cancer drug</b> boston.comopalapril-5/11/2000
2076 The abstracts are sumarized in yesterday's press releases. These are, howevStockDoc-4/6/2000
2075 Tuesday April 4, 12:51 pm Eastern Time Company Press Release SOURCE: EntreMedIlaine-4/5/2000
2074 The conference was last weekend, so the abstracts are probably already availablIlaine-4/4/2000
2073 Folkmans' group has been researching the molecular basis of angiogenesis anStockDoc-4/4/2000
2072 >>The news is contained in two studies. One, in The Journal of Clinical IIlaine-4/1/2000
2071 Actually they are not about Entremed. They are about using chemotherapy with sGregory Rasp-4/1/2000
2070 I didn't see the word "Entremed" in the articles. How do you knoInvestor2-4/1/2000
2069 The articles are about Entremed. They just came out today, in a major nationalIlaine-4/1/2000
2068 Another very nice story. Again, do you mind sharing how it is relevant to ENMDInvestor2-4/1/2000
2067 Very nice news story. Do you mind sharing how it is relevant to ENMD? Thanks,Investor2-4/1/2000
2066 I am not so sure this is news. Well obviously somebody feels it is. But, we hGregory Rasp-4/1/2000
2065 Canadian National Post Article Two Saturday, April 01, 2000 In mice and men, lzonkerharris-4/1/2000
2064 Canadian National Post Article one Saturday, April 01, 2000 Discovery could wzonkerharris-4/1/2000
2063 Today's Boston Globe Low doses of drugs successful vs. cancer By Richard Szonkerharris-4/1/2000
2062 EntreMed, Inc. Announces Commencement of Phase I Clinical Trial Of Orally-ActivGregory Rasp-3/31/2000
2061 Details of their agreement with CELG are outlined in their K-1's, however, RBlatch-3/19/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News